The Therapeutic Potential of MicroRNAs in Atrial Fibrillation

Abstract EN

One of the most globally prevalent supraventricular arrhythmias is atrial fibrillation (AF).

Knowledge of the structures and functions of messenger RNA (mRNA) has recently increased.

It is no longer viewed as solely an intermediate molecule between DNA and proteins but has come to be seen as a dynamic and modifiable gene regulator.

This new perspective on mRNA has led to rising interest in it and its presence in research into new therapeutic schemes.

This paper, therefore, focuses on microRNAs (miRNAs), which are small noncoding RNAs that regulate posttranscriptional gene expression and play a vital role in the physiology and normative development of cardiovascular systems.

This means they play an equally vital role in the development and progression of cardiovascular diseases.

In recent years, multiple studies have pinpointed particular miRNA expression profiles as being associated with varying histological features of AF.

These studies have been carried out in both animal models and AF patients.

The emergence of miRNAs as biomarkers and their therapeutic potential in AF patients will be discussed in the body of this paper.